Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iodine I 131 derlotuximab biotin

Drug Profile

Iodine I 131 derlotuximab biotin

Alternative Names: 131-I chTNT 1/B; 131-I-chTNT-1/B mAb; Cotara; Iodine-131 radiolabelled TNT monoclonal antibody; Monoclonal antibody TNT-1; TNT-1; Tumour necrosis therapy-1

Latest Information Update: 11 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Peregrine Pharmaceuticals
  • Developer Avid Bioservices; MediPharm Biotech
  • Class Antineoplastics; Iodine radioisotopes; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anaplastic astrocytoma; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Lung cancer
  • Phase II Glioblastoma

Most Recent Events

  • 05 Jan 2018 Peregrine Pharmaceuticals is now called Avid Bioservices
  • 12 Aug 2015 Phase-II development for Glioblastoma is ongoing in USA and India; advancement to phase III is dependent upon securing a partner
  • 06 Dec 2012 Peregrine plans a phase III trial for Glioblastoma (recurrent) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top